PRLD
Prelude Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$4.08
+7.94%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 18.01x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.43x
- Price / sales
- 14.52x
- Price / cash flow
- -9.79x
Enterprise value
- Enterprise value
- $191.5M
- EV / sales
- 8.54x
- EV / EBITDA
- -3.25x
- EV / EBIT
- -2.84x
- Market cap
- $325.6M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026